Napyradiomycin B4
Napyradiomycin B4 is a Napyradiomycin derivative, which inhibits the RANKL-induced MEK-ERK signaling pathway. Napyradiomycin B4 attenuates osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 111216-63-8
- Formel: C25H31Cl3O6
- Molecular Weight:533.87
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle MEK Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
10 μM
Compound: napyradiomycin B4
|
Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTS assay
Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTS assay
|
[PMID: 24328269] |
In Vitro
Napyradiomycin B4 (5 μM, 4 days) inhibits RANKL-induced osteoclast differentation[1].
Napyradiomycin B4 (5 μM, 4 days) promotes the expressions of Nrf2 related genes and inhibits the expressions of osteoclast related genes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BMMs
-
Concentration:1-5 μM
-
Incubation Time:4 days
-
Result:Revealed no evidence of F-actin ring.
-
Cell Line:BMMs
-
Concentration:1-5 μM
-
Incubation Time:4 days
-
Result:Reduced mRNA expressions of Nfatc1, Acp5, Dcstamp, Ctsk, and Mmp9.
Promoted mRNA expressions of Nrf2, Nqo1 and HO1.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Ligature-induced periodontitis in C57BL/J6 mice model[1]
-
Dosage:2-12 mg/kg
-
Administration:i.p. for 6 days
-
Result:Prevented the alveolar bone resorption and bone loss with high dose, inhibited osteoclast formation.
Chemical Information
-
CAS. Nr. 111216-63-8
-
Molecular Weight 533.87
-
Formel C25H31Cl3O6
-
SMILES
Cl[C@](C(C1=C(O)C=C(O)C=C1C2=O)=O)(C[C@H](C(C)(O3)C)Cl)[C@]23C[C@H]4C(C)([C@H](CC[C@@]4(O)C)Cl)C
-
Initial Source
marine-derived Streptomyces species
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Osteoclast differentiation from monocyte/macrophage precursors
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Napyradiomycin B4 Related Classifications
HY-N12740 Related Classifications
Powered by Bioz